Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 Oct;110(2):681–686. doi: 10.1111/j.1476-5381.1993.tb13865.x

Pharmacological characterization of the dopamine receptor coupled to cyclic AMP formation expressed by rat mesenteric artery vascular smooth muscle cells in culture.

A S Hall 1, S E Bryson 1, P F Vaughan 1, S G Ball 1, A J Balmforth 1
PMCID: PMC2175911  PMID: 7902178

Abstract

1. Mesenteric artery vascular smooth muscle cells derived from male Wistar rats and grown in culture were prelabelled with [3H]-adenine and exposed to a range of dopamine receptor agonists and antagonists. Resultant [3H]-cyclic AMP formation was determined and concentration-effect curves constructed, in the presence of propranolol (10-6) M) and the phosphodiesterase inhibitor IBMX (5 x 10(-4) M). 2. Ka apparent values for D1/DA1 dopamine receptor agonists SKF 38393, fenoldopam, 6,7-ADTN, and dopamine were 0.06, 0.59, 4.06 and 5.77 x 10(-6) M respectively. Although fenoldopam and SKF 38393 were more potent than dopamine, they were partial agonists with efficacies, relative to dopamine of approximately 48% and 24% respectively. 6,7-ADTN, in contrast, behaved as a full agonist. 3. Dopamine-stimulated cyclic AMP formation was inhibited in a concentration-dependent manner by the D1/DA1 dopamine receptor selective antagonists, SCH 23390 and cis-flupenthixol (Ki values 0.53 and 36.1 x 10(-1) M respectively). In contrast, the D2/DA2 dopamine receptor selective antagonists, domperidone and (-)-sulpiride, were less potent (Ki values 2.06 and 5.82 x 10(-6) M respectively). Furthermore, the stereoisomers of SCH 23390 and cis-flupenthixol, SCH 23388 and trans-flupenthixol, were at least two orders of magnitude less potent (Ki values 0.14 and 13.2 x 10(-6) M respectively) indicating the stereoselective nature of this receptor. 4. Our results indicate that rat mesenteric artery vascular smooth muscle cells in culture express a dopamine receptor coupled to cyclic AMP formation, which has the pharmacological profile, characteristic of the D1 dopamine receptor subfamily.

Full text

PDF
681

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen P. H., Gingrich J. A., Bates M. D., Dearry A., Falardeau P., Senogles S. E., Caron M. G. Dopamine receptor subtypes: beyond the D1/D2 classification. Trends Pharmacol Sci. 1990 Jun;11(6):231–236. doi: 10.1016/0165-6147(90)90249-8. [DOI] [PubMed] [Google Scholar]
  2. Balmforth A. J., Lyall F., Morton J. I., Ball S. G. Cultured mesenteric vascular smooth muscle cells express dopamine DA1-receptors. Eur J Pharmacol. 1988 Oct 18;155(3):305–308. doi: 10.1016/0014-2999(88)90519-5. [DOI] [PubMed] [Google Scholar]
  3. Balmforth A. J., Yasunari K., Vaughan P. F., Ball S. G. Characterization of dopamine and beta-adrenergic receptors linked to cyclic AMP formation in intact cells of the clone D384 derived from a human astrocytoma. J Neurochem. 1988 Nov;51(5):1510–1515. doi: 10.1111/j.1471-4159.1988.tb01119.x. [DOI] [PubMed] [Google Scholar]
  4. Barnett A., Ahn H. S., Billard W., Gold E. H., Kohli J. D., Glock D., Goldberg L. I. Relative activities of SCH 23390 and its analogs in three tests for D1/DA1 dopamine receptor antagonism. Eur J Pharmacol. 1986 Sep 9;128(3):249–253. doi: 10.1016/0014-2999(86)90772-7. [DOI] [PubMed] [Google Scholar]
  5. Brodde O. E. Vascular dopamine receptors: Demonstration and characterization by in vitro studies. Life Sci. 1982 Jul 26;31(4):289–306. doi: 10.1016/0024-3205(82)90406-4. [DOI] [PubMed] [Google Scholar]
  6. Brown E. M., Attie M. F., Reen S., Gardner D. G., Kebabian J., Aurbach G. D. Characterization of dopaminergic receptors in dispersed bovine parathyroid cells. Mol Pharmacol. 1980 Nov;18(3):335–340. [PubMed] [Google Scholar]
  7. Cavero I., Massingham R., Lefèvre-Borg F. Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents. Part I: Subclassification and functional description. Life Sci. 1982 Sep 6;31(10):939–948. doi: 10.1016/0024-3205(82)90165-5. [DOI] [PubMed] [Google Scholar]
  8. Cheng Y., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
  9. Cubeddu L., Barnes E. M., Langer S. Z., Weiner N. Release of norepinephrine and dopamine-beta-hydroxylase by nerve stimulation. I. Role of neuronal and extraneuronal uptake and of alpha presynaptic receptors. J Pharmacol Exp Ther. 1974 Sep;190(3):431–450. [PubMed] [Google Scholar]
  10. Dearry A., Gingrich J. A., Falardeau P., Fremeau R. T., Jr, Bates M. D., Caron M. G. Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature. 1990 Sep 6;347(6288):72–76. doi: 10.1038/347072a0. [DOI] [PubMed] [Google Scholar]
  11. Goldberg L. I., Kohli J. D. Peripheral pre- and post-synaptic dopamine receptors: are they different from dopamine receptors in the central nervous system? Commun Psychopharmacol. 1979;3(6):447–456. [PubMed] [Google Scholar]
  12. Gunther S., Alexander R. W., Atkinson W. J., Gimbrone M. A., Jr Functional angiotensin II receptors in cultured vascular smooth muscle cells. J Cell Biol. 1982 Feb;92(2):289–298. doi: 10.1083/jcb.92.2.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hall A. S., Bryson S. E., Ball S. G., Balmforth A. J. Pharmacological characterization of the beta-adrenoceptor coupled to cyclic AMP formation, expressed by rat mesenteric artery vascular smooth muscle cells in culture. J Hypertens Suppl. 1991 Dec;9(6):S96–S97. [PubMed] [Google Scholar]
  14. Hughes A., Sever P. Specific binding of 125I SCH 23982, a selective dopamine (D1) receptor ligand to plasma membranes derived from human kidney cortex. Biochem Pharmacol. 1989 Mar 1;38(5):781–785. doi: 10.1016/0006-2952(89)90231-1. [DOI] [PubMed] [Google Scholar]
  15. Hyttel J. SCH 23390 - the first selective dopamine D-1 antagonist. Eur J Pharmacol. 1983 Jul 15;91(1):153–154. doi: 10.1016/0014-2999(83)90381-3. [DOI] [PubMed] [Google Scholar]
  16. Kebabian J. W., Calne D. B. Multiple receptors for dopamine. Nature. 1979 Jan 11;277(5692):93–96. doi: 10.1038/277093a0. [DOI] [PubMed] [Google Scholar]
  17. Kotake C., Hoffmann P. C., Goldberg L. I., Cannon J. G. Comparison of the effects of dopamine and beta-adrenergic agonists on adenylate cyclase of renal glomeruli and striatum. Mol Pharmacol. 1981 Sep;20(2):429–434. [PubMed] [Google Scholar]
  18. Missale C., Castelletti L., Memo M., Carruba M. O., Spano P. F. Identification and characterization of postsynaptic D1- and D2-dopamine receptors in the cardiovascular system. J Cardiovasc Pharmacol. 1988 Jun;11(6):643–650. doi: 10.1097/00005344-198806000-00003. [DOI] [PubMed] [Google Scholar]
  19. Monsma F. J., Jr, Mahan L. C., McVittie L. D., Gerfen C. R., Sibley D. R. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6723–6727. doi: 10.1073/pnas.87.17.6723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Murthy V. V., Gilbert J. C., Goldberg L. I., Kuo J. F. Dopamine-sensitive adenylate cyclase in canine renal artery. J Pharm Pharmacol. 1976 Jul;28(7):567–571. doi: 10.1111/j.2042-7158.1976.tb02797.x. [DOI] [PubMed] [Google Scholar]
  21. Münch G., Raether A., Schöffel E., Illes P. Postsynaptic dopamine DA1- and DA2-receptors in jejunal arteries of rabbits. J Cardiovasc Pharmacol. 1991 Sep;18(3):468–471. doi: 10.1097/00005344-199109000-00021. [DOI] [PubMed] [Google Scholar]
  22. Nakajima T., Naitoh F., Kuruma I. Dopamine-sensitive adenylate cyclase in the rat kidney particulate preparation. Eur J Pharmacol. 1977 Jan 21;41(2):163–169. doi: 10.1016/0014-2999(77)90205-9. [DOI] [PubMed] [Google Scholar]
  23. Nichols A. J., Hiley C. R. Identification of adrenoceptors and dopamine receptors mediating vascular responses in the superior mesenteric arterial bed of the rat. J Pharm Pharmacol. 1985 Feb;37(2):110–115. doi: 10.1111/j.2042-7158.1985.tb05017.x. [DOI] [PubMed] [Google Scholar]
  24. Salomon Y., Londos C., Rodbell M. A highly sensitive adenylate cyclase assay. Anal Biochem. 1974 Apr;58(2):541–548. doi: 10.1016/0003-2697(74)90222-x. [DOI] [PubMed] [Google Scholar]
  25. Sibley D. R., Monsma F. J., Jr Molecular biology of dopamine receptors. Trends Pharmacol Sci. 1992 Feb;13(2):61–69. doi: 10.1016/0165-6147(92)90025-2. [DOI] [PubMed] [Google Scholar]
  26. Stoof J. C., Kebabian J. W. Two dopamine receptors: biochemistry, physiology and pharmacology. Life Sci. 1984 Dec 3;35(23):2281–2296. doi: 10.1016/0024-3205(84)90519-8. [DOI] [PubMed] [Google Scholar]
  27. Sunahara R. K., Guan H. C., O'Dowd B. F., Seeman P., Laurier L. G., Ng G., George S. R., Torchia J., Van Tol H. H., Niznik H. B. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991 Apr 18;350(6319):614–619. doi: 10.1038/350614a0. [DOI] [PubMed] [Google Scholar]
  28. Sunahara R. K., Niznik H. B., Weiner D. M., Stormann T. M., Brann M. R., Kennedy J. L., Gelernter J. E., Rozmahel R., Yang Y. L., Israel Y. Human dopamine D1 receptor encoded by an intronless gene on chromosome 5. Nature. 1990 Sep 6;347(6288):80–83. doi: 10.1038/347080a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES